Subscribers only

卵巢癌治療缺口補上一塊：鉑抗藥性病人加用新藥，死亡風險降三成五

卵巢癌一旦進入鉑抗藥性階段，治療選項驟減，病人常面臨不到一年的存活困境。美國FDA今年核准relacorilant合併白蛋白結合型紫杉醇（nab-paclitaxel，商品名：亞柏杉），第三期試驗顯示死亡風險降低35%、中位存活延長4.1個月。哪些病人適用？台灣目前能否取得？副作用又該注意什麼？

October 5, 2026

Reading time: 4 min

陳震宇醫師／編撰

卵巢癌是婦科癌症裡死亡率最高的一種，超過七成病人確診時已是晚期。多數人在接受手術與化療後，腫瘤短期內會明顯縮小，但只要治療反應維持不到六個月，或病情在停藥後半年內惡...

Upgrade your plan
Read the full article

This article is available to subscribers. Subscribe to read the full article and access personalized AI guidance, unlimited medication reminders, and more.

Full article access

Personalized AI guidance

Unlimited medication reminders

View plans Already subscribed? Sign in

卵巢癌治療缺口補上一塊：鉑抗藥性病人加用新藥，死亡風險降三成五

Upgrade your planRead the full article

Upgrade your plan
Read the full article